The Real-world Evidence (RWE) Solutions Market is expected to reach $4.9 billion by 2029, at a CAGR of 11.8% from 2022 to 2029. Real-world evidence (RWE) is clinical evidence gathered via RWD analysis on the use and potential benefits or risks of a medical product. RWE can be produced through various study designs or analyses, including but not limited to randomized trials, large simple trials, pragmatic trials, and observational studies (prospective or retrospective). RWE has several applications, including drug development life cycles, shortening development timelines, reducing the costs of clinical trials, and improving the probability of technical and regulatory success. The growing amount of big data in healthcare, shift from volume to value-based care, and rising focus on personalized healthcare are expected to positively impact the RWE solutions market.
Artificial Intelligence (AI) integration in RWE solutions: Current Industry Trend
Pharma companies are increasingly adopting AI-integrated RWE solutions that offer predictive models, machine/deep learning, probabilistic causal models, and unsupervised algorithms to characterize patients and establish matching techniques to compare groups of patients with related characteristics. AI-integrated RWE solutions enable pharma companies to derive deeper insights from rich patent data sets, better understand outcomes, drug performance, and differentiation at the subpopulation level, and generate hypotheses at scale across multiple therapies, comparisons, and endpoints.
An AI-integrated RWE analytics platform that delivers smart data processing, analysis, and outcomes offers an unparalleled opportunity to capitalize on these computing advancements. When used as part of an overall comprehensive RWE strategy, AI innovations can enhance drug development, improve patient treatment and access, and drive valuable new business opportunities.
The FDA continues to develop its regulations and guidelines in an effort to keep up with emerging digital health and data analytics trends. For instance, In January 2022, the FDA issued draft guidance on real-world evidence related to data sources, data standards, and regulatory considerations to promote understanding and use of RWD and RWE in the regulatory processes.
Similarly, in December 2021, the Center for Biologics Evaluation and Research (CBER), Center for Drug Evaluation and Research (CDER), and Center for Devices and Radiological Health (CDRH) issued draft guidance on the use of “Digital Health Technologies for Remote Data Acquisition in Clinical Investigations” which describes the use of computing platforms, software, and sensors to facilitate remote data acquisition during clinical investigations.
Many companies operating in the RWE market are taking various initiatives to integrate AI technology into their RWE solutions. For instance, in October 2021, Syneos Health, Inc. (U.S.) acquired RxDataScience (U.S.), a healthcare-focused data analytics, AI, and data management company. This acquisition was aimed at offering biopharmaceutical customers technology-enabled, insights-powered solutions to accelerate performance across the product lifecycle. RxDataScience’s product lifecycle solutions include scientific computing for R&D, decentralized trials, patient journey, RWE, predictive analytics, and commercial market research. Furthermore, RxDataScience provides an accelerated consulting-based model with an iterative approach to rapidly develop and deliver advanced analytics solution prototypes in six-to-eight-week sprints. The acquisition brings advanced solutions that range from basic reporting to sophisticated Augmented Intelligent Insights and Biopharma Analytics platforms.
Similarly, in September 2020, Parexel International Corporation (U.S.) acquired the Natural Language Processing (NLP) technology assets and completed the transfer of key personnel of Roam Analytics, Inc. (U.S.), a healthcare software company. This strategic move strengthened Parexel’s commitment to leveraging Artificial Intelligence (AI) and Machine Learning (ML) to drive innovations across drug development and life sciences. The acquisition also enhanced Parexel’s Pharmacovigilance and other Real-world data capabilities by utilizing NLP technology across the company’s various data sets to further streamline and extract insights from unstructured data.
Click here to: Get Free Sample Copy of this report
Key Findings in the RWE Solutions Market Study
Datasets Generated Larger Proportion of Revenue Compared to Consulting Services
The datasets segment is estimated to account for the largest share of the RWE solutions market in 2022. The large market share of this segment is attributed to the increasing need for additional insights on epidemiology, compliance, adherence, and costs in a realistic environment, the growing amount of medical data generated in hospitals, increasing dependence of outcome-based studies on real-world data, and rising demand for information regarding drug safety among payers, regulatory bodies, and providers.
Market Access & Reimbursement/Coverage Decisions to Dominate the Market
The market access & reimbursement/coverage decisions segment is estimated to account for the largest share of the RWE solutions market in 2022. The large market share of this segment is attributed to increasing demand for real-world data and real-world evidence to accelerate market access & reimbursement/coverage decisions, increasing investments by biopharmaceutical companies in R&D, and the growing inclination of regulatory bodies towards the use of real-world evidence (RWE).
Pharmaceutical & Medical Device Companies Segment to Account for the Largest Share of the RWE Solutions Market in 2022
The pharmaceutical & medical device companies segment is expected to account for the largest share of the RWE solutions marketin 2022. The large market share of this segment is attributed to the increasing relevance of RWE studies in drug development & approvals and assessing drug performance in real-world settings and the growing need to avoid costly drug recalls.
Asia-Pacific: Fastest-growing Regional Market
North America is expected to account for the largest share of the global RWE solutions market in 2022, followed by Asia-Pacific, Europe, Latin America, and the Middle East & Africa. However, Asia-Pacific is slated to register the fastest growth rate. The growth of this regional market is driven by the growing demand for data defining the value and effectiveness of medicines, the increasing need for conducting real-world studies in drug R&D, and the rising government initiatives for promoting the use of real-world studies for regulatory decision-making.
Key Players
The report includes a competitive landscape based on an extensive assessment of the key growth strategies adopted by leading market players from last four years. The key players profiled in the global RWE solutions market report include Anthem, Inc. (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), IBM Corporation (U.S.), ICON plc (Ireland), IQVIA (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), PPD, Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health (U.S.).
Scope of the Report:
RWE Solutions Market, by Component
(Note – Other Disparate Datasets include data generated from mobile devices, wearable devices, and social media)
RWE Solutions Market, by Application
(Note — Other Therapeutic Areas include infectious diseases, musculoskeletal disorders, dermatological diseases, and respiratory diseases)
(Note1 — Other Applications include regulatory and clinical decision-making)
RWE Solutions Market, by End User
(Note – Other end users include academic research institutions, patient advocacy groups, regulators, and health technology assessment agencies)
RWE Solutions Market, by Geography
Key questions answered in the report:
This market study covers the market sizes & forecasts of the various RWE solutions offered by key market players to support pharmaceutical, biotechnology, and medical device companies, healthcare payers, healthcare providers, and other end users in making key decisions related to market access & reimbursement/coverage decisions, drug development & approvals, post-market surveillance, medical device development & approvals. This report also involves the value analysis of various segments and subsegments of the RWE solutions market at the regional and country levels.
The global RWE solutions market is projected to reach $4.9 billion by 2029, at a CAGR of 11.8% during the forecast period.
Based on component, the datasets segment is estimated to account for the largest share of the RWE solutions market in 2022. The large market share of this segment is attributed to the increasing need for additional insights on epidemiology, compliance, adherence, and costs in a realistic environment, the growing amount of medical data generated in hospitals, increasing dependence of outcome-based studies on real-world data, and the rising demand for information regarding drug safety among payers, regulatory bodies, and providers.
The drug development & approvals segment is slated to register the highest CAGR during the forecast period due to increasing demand for real-world data and real-world evidence to accelerate drug discovery and development, increasing investments by biopharmaceutical companies in R&D, and the growing inclination of regulatory bodies towards the use of real-world evidence (RWE).
The rising incidence of chronic diseases, delays in drug development and the consequent increase in development costs, the increasing amount of big data in healthcare, the shift from volume to value-based care, and the rising focus on personalized healthcare are some of the factors expected to drive the growth of the RWE solutions market.
Furthermore, emerging markets, rising focus on end-to-end RWE services, and rising adoption of wearable devices and AI in RWE are expected to provide significant growth opportunities for existing market players and new entrants.
Emerging economies from Asia-Pacific, such as Japan and China, are projected to offer significant growth opportunities for the players operating in this market.
Key companies operating in the RWE solutions market are Anthem, Inc. (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), IBM Corporation (U.S.), ICON plc (Ireland), IQVIA (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), PPD, Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health (U.S.).
This report provides pre & post COVID-19 market estimates.
1. Introduction
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency
2. Research Methodology
2.1. Research Process
2.2. Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research
2.3. Market Assessment
2.3.1. Market Size Estimation
2.3.1.1. Bottom-up Approach
2.3.1.2. Top-down Approach
2.3.1.3. Growth Forecast
2.3.2. Market Share Analysis
2.4. Assumptions for the Study
2.5. Limitations for the Study
3. Executive Summary
4. Market Insights
4.1. Market Overview
4.2. Drivers
4.2.1. Rising Focus on Personalized Healthcare
4.2.2. Delays in Drug Development and the Consequent Increase in Development Costs
4.2.3. Growing Incidence of Chronic Diseases
4.2.4. Shift Toward Value-based Care
4.2.5. Rapidly Growing Big Data in the Healthcare Sector
4.3. Restraints
4.3.1. Reluctance to Rely on Real-World Studies
4.4. Opportunities
4.4.1. Emerging Economies
4.4.2. Rising Focus on end-to-end RWE Services
4.5. Challenges
4.5.1. Lack of Standardized Methodologies for Developing RWE
4.6. Key Market Trends
4.6.1. The Incorporation of Artificial Intelligence (AI) in the RWE Industry
4.6.1.1. The Adoption of AI Technologies is Growing in the Following Areas:
4.6.1.1.1. Clinical Trials Design
4.6.1.1.2. Modeling and Forecasting Patient Enrichment & Recruitment
4.6.1.1.3. Selecting Investigator Site
4.6.1.1.4. Patient Monitoring & Managing and Medication Adherence & Retention
4.6.1.1.5. AI-enabled Clinical Trial Analytics
4.6.1.1.6. Outsourcing Essential AI Solutions Via Strategic Partnerships & Collaborations
4.6.1.1.7. Market Access Using AI Solutions
4.6.1.1.8. Post-market Surveillance Using AI Solutions
4.6.1.2. Case Studies for AI-based RWE Solutions
4.6.1.2.1. AI-based RWE Solutions for Medical Device Post-market Studies - Huma.AI (U.S.)
4.6.1.2.2. AI-enabled RWE Solutions to Support Clinical Decision-making in Drug Research and Development - Owkin, Inc. (France)
4.6.1.2.3. AI-integrated RWE Solutions for Market Access - Medaffcon Oy (Finland)
4.6.1.2.4. Leveraging Real-world Data Insights Using AI and Machine Learning Algorithms – Aetion, Inc. (U.S.) & Quinten Health (France)
4.6.1.2.5. AI-powered Real-world Medical Imaging – Life Image Inc. (U.S.)
4.6.1.2.6. AI-powered RWE Platform to Track Adverse Events - Data2life (Israel)
4.6.1.2.7. AI-powered RWE Solutions to Predict Patients' Health at Critical Care Units - Phastar (U.K.)
4.6.2. Growing Adoption of RWE in Drug Development and Commercialization
4.6.3. Rising Number of Consolidations
4.6.4. Improved Patient Outcomes and Value Creation From Real-world Evidence
4.7. The Impact of COVID-19
5. Real-world Evidence (RWE) Solutions Market: Regulatory Analysis
5.1. Introduction
5.2. North America
5.3. Europe
5.4. Asia-Pacific
5.5. Rest of the World
6. Pricing Models (Emr/Genomic/Integrated Datasets)
6.1. Introduction
6.2. Pay Per Patient Record (Volume-based Pricing)
6.3. Pay Per Usage (Value-based Pricing)
6.4. Annual Subscription
7. Real-world Evidence Solutions Market, by Component
7.1. Introduction
7.2. Datasets
7.2.1. Disparate Datasets
7.2.1.1. EMR/EHR/Clinical Data
7.2.1.2. Claims & Billing Data
7.2.1.3. Pharmacy Data
7.2.1.4. Product/Disease Registries Data
7.2.1.5. Other Disparate Datasets
7.2.2. Integrated Datasets
7.3. Consulting & Analytics
8. Real-world Evidence Solutions Market, by Application
8.1. Introduction
8.2. Market Access & Reimbursement/Coverage Decisions
8.3. Drug Development & Approvals
8.3.1. Oncology
8.3.2. Neurology
8.3.3. Immunology
8.3.4. Cardiovascular Diseases
8.3.5. Other Therapeutic Areas
8.4. Medical Device Development & Approvals
8.5. Post-market Surveillance
8.6. Clinical & Regulatory Decision-making
9. Real-world Evidence Solutions Market, by End User
9.1. Introduction
9.2. Pharmaceutical, Biotechnology, and Medical Device Companies
9.3. Healthcare Payers
9.4. Healthcare Providers
9.5. Other End Users
10. Real-world Evidence Solutions Market, by Geography
10.1. Introduction
10.2. North America
10.2.1. U.S.
10.2.2. Canada
10.3. Europe
10.3.1. U.K.
10.3.2. Germany
10.3.3. France
10.3.4. Italy
10.3.5. Spain
10.3.6. Rest of Europe
10.4. Asia-Pacific
10.4.1. Japan
10.4.2. China
10.4.3. India
10.4.4. South Korea
10.4.5. Taiwan
10.4.6. Singapore
10.4.7. Rest of Asia-Pacific
10.5. Latin America
10.6. Middle East & Africa
11. Competitive Landscape
11.1. Introduction
11.2. Key Growth Strategies
11.3. Competitive Benchmarking
11.4. Market Share Analysis (2021)
11.4.1. IQVIA Holdings, Inc. (U.S.)
11.4.2. ICON Plc (Ireland)
11.4.3. PPD Inc. (U.S.)
12. Company Profiles (Business Overview, Financial Overview, Product Portfolio, Strategic Developments)
12.1. IQVIA Holdings Inc.
12.2. PPD Inc.
12.3. ICON Plc
12.4. Parexel International Corporation
12.5. UnitedHealth Group Incorporated
12.6. Flatiron Health, Inc.
12.7. Oracle Corporation
12.8. SAS Institute, Inc.
12.9. Anthem, Inc.
12.10. Clinigen Group Plc
12.11. Cognizant Technology Solutions Corporation
12.12. PerkinElmer, Inc.
13. Appendix
13.1. Questionnaire
13.2. Available Customization
List of Tables
Table 1 Global Real-world Evidence Solutions Market Drivers: Impact Analysis, (2022–2029)
Table 2 Total Cost Per Study, by Phase and Therapeutic Area (USD Million)
Table 3 Number of Persons Aged 65 Years or Above, by Region (2019 VS. 2050)
Table 4 Sources of Healthcare Data
Table 5 Global Real-world Evidence Solutions Market Restraints: Impact Analysis (2022–2029)
Table 6 Strategic Developments of Key Players Related to the Integration of AI Into RWE Solutions
Table 7 RWE in Latin American Countries
Table 8 Observed Indicative Prices of Real-world Data by Type (USD Per Patient Record)
Table 9 Global Real-world Evidence Solutions Market Size, by Component, 2020–2029 (USD Million)
Table 10 Global Real-world Evidence Solutions Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 11 Real-world Evidence Solutions Datasets Market Size, by Country/Region, 2020–2029 (USD Million)
Table 12 Global RWE Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 13 RWE Disparate Datasets Market Size, by Country/Region, 2020–2029 (USD Million)
Table 14 RWE EMR/EHR/Clinical Data Market Size, by Country/Region, 2020–2029 (USD Million)
Table 15 RWE Claims & Billing Data Market Size, by Country/Region, 2020–2029 (USD Million)
Table 16 RWE Pharmacy Data Market Size, by Country/Region, 2020–2029 (USD Million)
Table 17 RWE Product/Disease Registries Data Market Size, by Country/Region, 2020–2029 (USD Million)
Table 18 Other RWE Disparate Datasets Market Size, by Country/Region, 2020–2029 (USD Million)
Table 19 RWE Integrated Datasets Market Size, by Country/Region, 2020–2029 (USD Million)
Table 20 RWE Consulting & Analytics Market Size, by Country/Region, 2020–2029 (USD Million)
Table 21 Global Real-world Evidence Solutions Market Size, by Application, 2020–2029 (USD Million)
Table 22 Global RWE Solutions Market Size for Market Access & Reimbursement/Coverage Decisions, by Country/Region, 2020–2029 (USD Million)
Table 23 Global RWE Solutions Market Size for Drug Development & Approvals, by Therapeutic Area, 2020–2029 (USD Million)
Table 24 Global RWE Solutions Market Size for Drug Development & Approvals, by Country/Region, 2020–2029 (USD Million)
Table 25 Oncology: Drugs in the R&D Pipeline
Table 26 Global RWE Solutions Market Size for Oncology, by Country/Region, 2020–2029 (USD Million)
Table 27 Neurology: Drugs in the R&D Pipeline
Table 28 Global RWE Solutions Market Size for Neurology, by Country/Region, 2020–2029 (USD Million)
Table 29 Immunology: Drugs in the R&D Pipeline
Table 30 Global RWE Solutions Market Size for Immunology, by Country/Region, 2020–2029 (USD Million)
Table 31 Medical Costs Associated With Cardiovascular Diseases (2010–2030) ( USD Billion)
Table 32 Cardiovascular Diseases: Drugs in the R&D Pipeline
Table 33 Global RWE Solutions Market Size for Cardiovascular Diseases, by Country/Region, 2020–2029 (USD Million)
Table 34 Other Therapeutic Areas: Drugs in the R&D Pipeline
Table 35 Global RWE Solutions Market Size for Other Therapeutic Areas, by Country/Region, 2020–2029 (USD Million)
Table 36 Global RWE Solutions Market Size for Medical Device Development & Approvals, by Country/Region, 2020–2029 (USD Million)
Table 37 Global RWE Solutions Market Size for Post-market Surveillance, by Country/ Region, 2020–2029 (USD Million)
Table 38 Global RWE Solutions Market Size for Clinical & Regulatory Decision-Making, by Country/Region, 2020–2029 (USD Million)
Table 39 Global RWE Solutions Market Size, by End User, 2020–2029 (USD Million)
Table 40 Global RWE Solutions Market Size for Pharmaceutical, Biotechnology, and Medical Device Companies, by Country/Region, 2020–2029 (USD Million)
Table 41 Global RWE Solutions Market Size for Healthcare Payers, by Country/Region, 2020–2029 (USD Million)
Table 42 Global RWE Solutions Market Size for Healthcare Providers, by Country/Region, 2020–2029 (USD Million)
Table 43 Global RWE Solutions Market Size for Other End Users, by Country/Region, 2020–2029 (USD Million)
Table 44 Global Real-world Evidence Solutions Market, by Country/Region, 2020–2029 (USD Million)
Table 45 North America: Real-world Evidence Solutions Market Size, by Country, 2020–2029 (USD Million)
Table 46 North America: Real-world Evidence Solutions Market Size, by Component, 2020–2029 (USD Million)
Table 47 North America: RWE Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 48 North America: RWE Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 49 North America: Real-world Evidence Solutions Market Size, by Application, 2020–2029 (USD Million)
Table 50 North America: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2020–2029 (USD Million)
Table 51 North America: RWE Solutions Market Size, by End User, 2020–2029 (USD Million)
Table 52 U.S.: Real-world Evidence Solutions Market Size, by Component, 2020–2029 (USD Million)
Table 53 U.S.: RWE Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 54 U.S.: RWE Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 55 U.S.: Real-world Evidence Solutions Market Size, by Application, 2020–2029 (USD Million)
Table 56 U.S.: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2020–2029 (USD Million)
Table 57 U.S.: RWE Solutions Market Size, by End User, 2020–2029 (USD Million)
Table 58 Number of Active Clinical Trials in Canada, by Condition, 2020
Table 59 Canada: Real-world Evidence Solutions Market Size, by Component, 2020–2029 (USD Million)
Table 60 Canada: RWE Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 61 Canada: RWE Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 62 Canada: Real-world Evidence Solutions Market Size, by Application, 2020–2029 (USD Million)
Table 63 Canada: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2020–2029 (USD Million)
Table 64 Canada: RWE Solutions Market Size, by End User, 2020–2029 (USD Million)
Table 65 Europe: Real-world Evidence Solutions Market Size, by Country/Region, 2020–2029 (USD Million)
Table 66 Europe: Real-world Evidence Solutions Market Size, by Component, 2020–2029 (USD Million)
Table 67 Europe: RWE Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 68 Europe: RWE Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 69 Europe: Real-world Evidence Solutions Market Size, by Application, 2020–2029 (USD Million)
Table 70 Europe: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2020–2029 (USD Million)
Table 71 Europe: RWE Solutions Market Size, by End User, 2020–2029 (USD Million)
Table 72 U.K.: Conferences and Workshops on Real-world Evidence Solutions
Table 73 U.K.: Real-world Evidence Solutions Market Size, by Component, 2020–2029 (USD Million)
Table 74 U.K.: RWE Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 75 U.K.: RWE Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 76 U.K.: Real-world Evidence Solutions Market Size, by Application, 2020–2029 (USD Million)
Table 77 U.K.: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2020–2029 (USD Million)
Table 78 U.K.: RWE Solutions Market Size, by End User, 2020–2029 (USD Million)
Table 79 Conferences, Symposia, and Workshops in Germany
Table 80 Germany: Real-world Evidence Solutions Market Size, by Component, 2020–2029 (USD Million)
Table 81 Germany: RWE Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 82 Germany: RWE Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 83 Germany: Real-world Evidence Solutions Market Size, by Application, 2020–2029 (USD Million)
Table 84 Germany: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2020–2029 (USD Million)
Table 85 Germany: RWE Solutions Market Size, by End User, 2020–2029 (USD Million)
Table 86 France: Real-world Evidence Solutions Market Size, by Component, 2020–2029 (USD Million)
Table 87 France: RWE Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 88 France: RWE Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 89 France: Real-world Evidence Solutions Market Size, by Application, 2020–2029 (USD Million)
Table 90 France: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2020–2029 (USD Million)
Table 91 France: RWE Solutions Market Size, by End User, 2020–2029 (USD Million)
Table 92 Italy: Real-world Evidence Solutions Market Size, by Component, 2020–2029 (USD Million)
Table 93 Italy: RWE Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 94 Italy: RWE Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 95 Italy: Real-world Evidence Solutions Market Size, by Application, 2020–2029 (USD Million)
Table 96 Italy: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2020–2029 (USD Million)
Table 97 Italy: RWE Solutions Market Size, by End User, 2020–2029 (USD Million)
Table 98 Spain: Real-world Evidence Solutions Market Size, by Component, 2020–2029 (USD Million)
Table 99 Spain: RWE Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 100 Spain: RWE Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 101 Spain: Real-world Evidence Solutions Market Size, by Application, 2020–2029 (USD Million)
Table 102 Spain: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2020–2029 (USD Million)
Table 103 Spain: RWE Solutions Market Size, by End User, 2020–2029 (USD Million)
Table 104 Rest of Europe: Real-world Evidence Solutions Market Size, by Component, 2020–2029 (USD Million)
Table 105 Rest of Europe: RWE Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 106 Rest of Europe: RWE Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 107 Rest of Europe: Real-world Evidence Solutions Market Size, by Application, 2020–2029 (USD Million)
Table 108 Rest of Europe: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2020–2029 (USD Million)
Table 109 Rest of Europe: RWE Solutions Market Size, by End User, 2020–2029 (USD Million)
Table 110 Asia-Pacific: Real-world Evidence Solutions Market Size, by Country/Region, 2020–2029 (USD Million)
Table 111 Asia-Pacific: Real-world Evidence Solutions Market Size, by Component, 2020–2029 (USD Million)
Table 112 Asia-Pacific: RWE Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 113 Asia-Pacific: RWE Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 114 Asia-Pacific: Real-world Evidence Solutions Market Size, by Application, 2020–2029 (USD Million)
Table 115 Asia-Pacific: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2020–2029 (USD Million)
Table 116 Asia-Pacific: RWE Solutions Market Size, by End User, 2020–2029 (USD Million)
Table 117 Japan: Real-world Evidence Solutions Market Size, by Component, 2020–2029 (USD Million)
Table 118 Japan: RWE Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 119 Japan: RWE Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 120 Japan: Real-world Evidence Solutions Market Size, by Application, 2020–2029 (USD Million)
Table 121 Japan: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2020–2029 (USD Million)
Table 122 Japan: RWE Solutions Market Size, by End User, 2020–2029 (USD Million)
Table 123 Diversified Real-World Data Sources in China
Table 124 China: Real-world Evidence Solutions Market Size, by Component, 2020–2029 (USD Million)
Table 125 China: RWE Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 126 China: RWE Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 127 China: Real-world Evidence Solutions Market Size, by Application, 2020–2029 (USD Million)
Table 128 China: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2020–2029 (USD Million)
Table 129 China: RWE Solutions Market Size, by End User, 2020–2029 (USD Million)
Table 130 India: Real-world Evidence Solutions Market Size, by Component, 2020–2029 (USD Million)
Table 131 India: RWE Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 132 India: RWE Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 133 India: Real-world Evidence Solutions Market Size, by Application, 2020–2029 (USD Million)
Table 134 India: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2020–2029 (USD Million)
Table 135 India: RWE Solutions Market Size, by End User, 2020–2029 (USD Million)
Table 136 South Korea: Real-world Evidence Solutions Market Size, by Component, 2020–2029 (USD Million)
Table 137 South Korea: RWE Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 138 South Korea: RWE Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 139 South Korea: Real-world Evidence Solutions Market Size, by Application, 2020–2029 (USD Million)
Table 140 South Korea: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2020–2029 (USD Million)
Table 141 South Korea: RWE Solutions Market Size, by End User, 2020–2029 (USD Million)
Table 142 RWE Sources in Taiwan
Table 143 Taiwan: Real-world Evidence Solutions Market Size, by Component, 2020–2029 (USD Million)
Table 144 Taiwan: RWE Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 145 Taiwan: RWE Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 146 Taiwan: Real-world Evidence Solutions Market Size, by Application, 2020–2029 (USD Million)
Table 147 Taiwan: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2020–2029 (USD Million)
Table 148 Taiwan: RWE Solutions Market Size, by End User, 2020–2029 (USD Million)
Table 149 Singapore: Real-world Evidence Solutions Market Size, by Component, 2020–2029 (USD Million)
Table 150 Singapore: RWE Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 151 Singapore: RWE Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 152 Singapore: Real-world Evidence Solutions Market Size, by Application, 2020–2029 (USD Million)
Table 153 Singapore: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2020–2029 (USD Million)
Table 154 Singapore: RWE Solutions Market Size, by End User, 2020–2029 (USD Million)
Table 155 Estimated Number of New Cancer Cases From 2020 to 2030
Table 156 ROAPAC: Real-world Evidence Solutions Market Size, by Component, 2020–2029 (USD Million)
Table 157 RoAPAC: RWE Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 158 RoAPAC: RWE Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 159 RoAPAC: Real-world Evidence Solutions Market Size, by Application, 2020–2029 (USD Million)
Table 160 RoAPAC: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2020–2029 (USD Million)
Table 161 RoAPAC: RWE Solutions Market Size, by End User, 2020–2029 (USD Million)
Table 162 Latin America: Real-world Evidence Solutions Market Size, by Component, 2020–2029 (USD Million)
Table 163 Latin America: RWE Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 164 Latin America: RWE Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 165 Latin America: Real-world Evidence Solutions Market Size, by Application, 2020–2029 (USD Million)
Table 166 Latin America: RWE Market Size for Drug Development & Approvals, by Therapeutic Area, 2020–2029 (USD Million)
Table 167 Latin America: RWE Solutions Market Size, by End User, 2020–2029 (USD Million)
Table 168 Middle East & Africa: Real-world Evidence Solutions Market Size, by Component, 2020–2029 (USD Million)
Table 169 Middle East & Africa: RWE Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 170 Middle East & Africa: RWE Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)
Table 171 Middle East & Africa: Real-world Evidence Solutions Market Size, by Application, 2020–2029 (USD Million)
Table 172 Middle East & Africa: RWE Market Size for Drug Development & Approvals, byTherapeutic Area, 2020–2029 (USD Million)
Table 173 Middle East & Africa: RWE Solutions Market Size, by End User, 2020–2029 (USD Million)
Table 174 Recent Developments, by Company, 2018–2022
List of Figures
Figure 1 Key Stakeholders
Figure 2 Research Process
Figure 3 Key Secondary Sources
Figure 4 Primary Research Techniques
Figure 5 Key Executives Interviewed
Figure 6 Breakdown of Primary Interviews (Supply-side & Demand-side)
Figure 7 Market Size Estimation
Figure 8 Global Real-world Evidence Solutions Market, by Component, 2022 Vs. 2029 (USD Million)
Figure 9 Global Real-world Evidence Solutions Market, by Application, 2022 Vs. 2029 (USD Million)
Figure 10 Global Real-world Evidence Solutions Market, by End User, 2022 Vs. 2029 (USD Million)
Figure 11 Global Real-world Evidence Solutions Market, by Geography
Figure 12 Market Dynamics
Figure 13 Percentage of Personalized Medicines Approved (2015–2020)
Figure 14 U.S.: Number of People With Chronic Conditions (2000–2030)
Figure 15 Asia-Pacific: Percent Share of Global Clinical Trial Activities (2012–2020)
Figure 16 Global Real-world Evidence Solutions Market Size, by Component, 2022 Vs. 2029 (USD Million)
Figure 17 U.S.: Number of E-Prescriptions, 2013–2020 (Billions)
Figure 18 Global Real-world Evidence Solutions Market Size, by Application, 2022–2029 (USD Million)
Figure 19 Estimated Number of New Cancer Cases, by Region, 2020–2040 (In Millions)
Figure 20 Global Real-world Evidence Solutions Market Size, by End User, 2022 Vs. 2029 (USD Million)
Figure 21 Pharmaceutical R&D Spending, 2012–2026 ( USD Billion)
Figure 22 Global Real-world Evidence Solutions Market, by Region, 2022–2029 (USD Million)
Figure 23 North America: Real-world Evidence Solutions Market Snapshot
Figure 24 Number of Novel Drug Approvals by Cder From 2010 To 2020
Figure 25 Europe: Real-world Evidence Solutions Market Snapshot
Figure 26 Pharmaceutical Industry R&D Expenditure in Germany, 2016–2019 (USD Million)
Figure 27 France: Share of Population Aged 65 & Above, 2010–2020
Figure 28 Italy: Share of Population Aged 65 Years and Above, 2015–2020
Figure 29 Pharmaceutical R&D Expenditure in Spain, 2016–2019 (USD Million)
Figure 30 Pharmaceutical R&D Expenditure in European Countries, 2016–2019 (USD Million)
Figure 31 Asia-Pacific: Real-world Evidence Solutions Market Snapshot
Figure 32 Number of People >65 Years of Age in Japan, 2000–2050
Figure 33 Key Growth Strategies Adopted by Leading Players (2018–2022)
Figure 34 Real-world Evidence Solutions: Competitive Benchmarking
Figure 35 Market Share Analysis: Real-world Evidence Solutions Industry (2021)
Figure 36 Financial Overview (2019–2021): IQVIA Holdings Inc.
Figure 37 Financial Overview (2018–2020): PPD Inc.
Figure 38 Financial Overview (2019–2021): ICON Plc
Figure 39 Financial Overview (2019–2021): UnitedHealth Group Incorporated
Figure 40 Financial Overview (2019–2021): Oracle Corporation
Figure 41 Financial Overview (2020–2021): SAS Institute Inc.
Figure 42 Financial Overview (2019–2021): Anthem, Inc.
Figure 43 Financial Overview (2019–2021): Clinigen Group Plc
Figure 44 Financial Overview (2019–2021): Cognizant Technology Solutions Corporation
Figure 45 Financial Overview (2019–2022): PerkinElmer, Inc.
This report provides pre & post COVID-19 market estimates.
Published Date: Oct-2022
Published Date: Sep-2022
Published Date: Aug-2022
Published Date: Aug-2022
Published Date: Aug-2022
